Could blocking ‘jumping genes’ help fight disease and aging? The first clinical trials are testing inhibitors of transposons, DNA sequences that hop around the genome on their own

Such a great article by Mitch Leslie in @science.org about the potential of inhibiting LINE-1 RT – a genomic, virus-like repetitive element – to address a spectrum of diseases, including ROME’s focus: #neurodegenerative and #autoimmune diseases. www.science.org/content/arti...
#darkgenome

Thrilled to announce this publication – many congrats to all of the ROMANS who contributed to this landmark research & to our esteemed academic collaborators, too! Targeting LINE-1 RT may be key to addressing unmet needs for many diseases. We’re proud to be a #darkgenome & LINE-1 RT pioneer!
Rosana

We’re excited to announce a new publication in Nature Communications: the first large-scale, pan-cancer analysis of LINE-1 expression levels and retrotransposition (RT) activity. These data demonstrate the potential for precision LINE-1 RT-targeted therapeutic approaches. rometx.com/press-releas...

Hello, Bluesky! We’re excited to be part of the growing science and biotech community here. We’ll see many of you at #JPM25. #BioSky